MorphoSys CEO Says Strategy To Build Proprietary Pipeline 'On Track'

 
• By Sten Stovall

MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.

Coins
MorphoSys CEO Says EU and US Tremfya Sales Will Help Fund A Proprietary Pipeline • Source: Shutterstock

More from New Products

More from Scrip